Clinical cancer research : an official journal of the American Association for Cancer Research · 2023-08-15
This paper combines preclinical DR5-antibody characterization with exploratory phase 1 chondrosarcoma findings. It reports antitumor activity and safety observations in small cohorts and identifies the later randomized ChonDRAgon trial as further evaluation.
Program relevance
The paper directly studies INBRX-109 in chondrosarcoma, including phase 1 cohorts; it predates randomized ChonDRAgon results.
Formulation / population: Intravenous INBRX-109, the DR5 agonist antibody later named ozekibart.
Mixed preclinical and phase 1 clinical evidence.
Not a randomized ChonDRAgon phase 2 results publication.
Clinical Trial, Phase I / Journal Article / Research Support, N.I.H., Extramural / Research Support, Non-U.S. Gov't